ABSTRACT
<p><b>OBJECTIVE</b>We aim to explore the potential association between serum gamma-glutamyl transferase levels and functional outcome after aneurysmal subarachnoid hemorrhage in a Chinese population.</p><p><b>METHODS</b>A total of 386 aneurysmal subarachnoid hemorrhage patients were included in the study from September 2007 to February 2015. Baseline serum gamma-glutamyl transferase levels and 6-month follow-up functional outcomes were determined. A poor outcome was defined as a modified ranking scale score of ⋝ 3. The multivariable logistic model was used to analyze the relationship between serum gamma-glutamyl transferase and clinical outcomes after aneurysmal subarachnoid hemorrhage.</p><p><b>RESULTS</b>The adjusted poor outcome rates of patients with gamma-glutamyl transferase levels of < 30 U/L, 30-50 U/L and ⋝ 50 U/L were 16.7%, 19.6%, and 34.4%, respectively (P < 0.01). The age-sex and multivariable adjusted odds ratios (95% confidence intervals) of poor prognosis comparing the top group (⋝ 50 U/L) with the lowest group (< 30 U/L) were 5.76 (2.74-12.13), 6.64 (2.05-21.52), and 6.36 (1.92-21.02). A significant linear trend existed between gamma-glutamyl transferase level and aneurysmal subarachnoid hemorrhage prognosis. This association was also observed among nondrinkers.</p><p><b>CONCLUSION</b>Patients with higher gamma-glutamyl transferase levels were more likely to have a poor prognosis. Serum gamma-glutamyl transferase can be considered to be an independent predictor of functional outcomes after aneurysmal subarachnoid hemorrhage.</p>
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Follow-Up Studies , Gene Expression Regulation, Enzymologic , Predictive Value of Tests , Subarachnoid Hemorrhage , Blood , gamma-Glutamyltransferase , BloodABSTRACT
AIM:To investigate the combination therapeutic effect of Ginkgobalide B (GKB) and retinal stem cells (RSCs)transplantation on glaucoma in rats.METHODS:Rats were divided randomly into five groups:control group,glaucoma group,RSCs group,GKB group and RSCs combination therapy group.A chronic glaucoma model was established in rats,accordingly.The morphological changes in ocular tissues were analyzed by HE staining.Retinal ganglion cells apoptosis were analyzed by TUNEL staining.The protein expressions of Bcl-2,Bax,Cleaved caspase-3 and Cleaved caspase-9 were determined by Western blot.The mRNA levels of Bcl-2 and Bax were determined by qPCR.RESULTS:HE staining revealed that RSCs transplantation or GKB treatment decreased fiber interstitial edema and vacuole,as compared to glaucoma group.Furthermore,this improvement was more pronounced in combination therapy group than in single treatment alone.Combination therapy significantly inhibited retinal ganglion cells apoptosis,increased Bcl-2 mRNA and protein expression,but decreased Bax mRNA and protein expression.Moreover,the protein expression of Cleaved caspase-3 and Cleaved caspase-9 expression were decreased after combination therapy.CONCLUSION:Our data demonstrate that combination of Ginkgobalide B and retinal stem cells transplantation can inhibit retinal ganglion cells apoptosis and protect against glaucoma.These effects may be associated with the regulation of Bcl-2,Bax,Cleaved caspase-3 and Cleaved caspase-9 expression.
ABSTRACT
Objective To explore the correlation between CD62p and clopidogrel resistance in patients undergoing percutaneous coronary intervention with coronary heart disease combined with diabetes mellitus.Methods 150 patients ndergoing percutaneous coronary intervention with coronary heart disease combined with diabetes mellitus were enrolled in our hospital from August 2013 to December 2016,of all patients accepted clopidogrel treatment,the platelet aggregation rate were analyzed before and after treatment,which all patients divided into two groups as the range of decreasing platelet aggregation rate whether ≥ 10％,clopidogrel effective group (C2) and clopidogrel resistance group (C 1) were detected CD62p and platelet aggregation maximum (PAGM),the relevance of which range with platelet aggregation rate was analyzed.Results After treatment,the platelet aggregation rate of all patient decreased signifieantly (P ＜ 0.05).Of all patients divided into clopidogrel effective group (C2) and clopidogrel resistance group (C 1) as the range of decreasing platelet aggregation rate,and the CD62p of Group C1 decreased compared with before treatment (P ＜ 0.05),the level of CD62p and PAGM in Group C2 were decreasing compared with pre-treatment,and the range of which was larger than those Group C1 (P ＜ 0.05).The reference of CD62p and PAGM in Group C2 (r =0.424,P =0.001) was better than that Group C1 (r =0.387,P =0.020).Conclusions Clopidogrel for patients undergoing percutaneous coronary intervention with coronary heart disease combined with diabetes mellitus possessed inhibition for platelet activity,and clopidogrel resistance might be associated with platelet activity.
ABSTRACT
Observational studies between magnesium int- ake and risk of type 2 diabetes yielded inconsistent results. We conducted a system literature search of PubMed database through March 2015 for prospective cohort studies of magnesium intake and type 2 diabetes risk. Study-specific results were pooled in a random-effects model. Subgroup and sensitivity analysis were performed to assess the potential sources of heterogeneity and the robustness of the pooled estimation. Generalized least squares trend estimation was used to investigate the dose-response relationship. A total of 15 papers with 19 analyses were identified with 539,735 participants and 25,252 incident diabetes cases. Magnesium intake was associated with a significant lower risk of type 2 diabetes (RR: 0.77; 95% CI: 0.71-0.82) for the highest compared with lowest category. This association was not significantly modified by the pre-specified study characteristics. In the dose-response analysis, a magnesium intake increment of 100 mg/day was associated with a 16% reduction in type 2 diabetes risk (RR: 0.84; 95% CI: 0.80-0.88). A nonlinear relationship existed between magnesium intake and type 2 diabetes (P-nonlinearity=0.003). This meta-analysis further verified a protective effect of magnesium intake on type 2 diabetes in a nonlinear dose-response manner.
Subject(s)
Humans , Diabetes Mellitus, Type 2 , Epidemiology , Dose-Response Relationship, Drug , Least-Squares Analysis , Magnesium , Blood , Nonlinear Dynamics , Prospective Studies , RiskABSTRACT
<p><b>OBJECTIVE</b>To observe the therapeutic effect of shengxuening (SXN) in treating iron-deficiency anemia (IDA) and to explore its molecular mechanism on iron metabolism balance regulation.</p><p><b>METHODS</b>Patients with IDA were randomly divided into the treated group and the control group, 50 in each group. They were treated with SXN (0.1 g, three times per day) and ferrous gluconate (0.1 g, three times per day) respectively, for 30 days. Levels of serum iron (Fe), total iron binding capacity (TIBC), transferrin saturation (TS), serum ferritin (SF), transferrin (Tf), soluble transferrin receptor (sTfR) and blood routine test, as well as scoring of TCM qi-blood deficiency Syndrome were conducted before and after treatment.</p><p><b>RESULTS</b>The total effective rate in the treated group reached 92%, it was shown that SXN could improve the iron metabolism, increase levels of Fe, TS, SF and reduce levels of TIBC, Tf, sTfR, it has obvious effect in promoting erythrocyte generation and could promote formation of leucocytes and platelets. The total effective rate in the control group was 32%, which was significantly lower than that in the treated group (P < 0.01).</p><p><b>CONCLUSION</b>The effect of SXN in treating IDA and qi-blood deficiency Syndrome is evident, it could improve the iron metabolism, increase levels of Fe, TS, SF and lower levels of TIBC, Tf, sTfR.</p>